Efficacy and safety of leflunomide in active rheumatoid arthritis

Rheumatology

Volumn 39, Issue SUPPL. 1, 2000, Pages 48-56

  Smolen, J S ^a   Emery, P ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Efficacy and safety; Leflunomide; Methotrexate; Placebo controlled randomized trials; Rheumatoid arthritis; Sulphasalazine

Indexed keywords

FOLIC ACID; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; PYRIMIDINE; SALAZOSULFAPYRIDINE;

ALOPECIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; META ANALYSIS; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SYMPTOM;

EID: 0034040472     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.rheumatology.a031495     Document Type: Conference Paper

References (37)

1. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
2. Emery P. The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 1994;33:765-81.
3. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol 1998;25:408-16.
4. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
5. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
6. Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol 1997;15(suppl. 17):75-81.
7. Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 1993;14:381-94.
8. waf-1 pathways. Arthritis Rheum 1997;40(suppl. 9):S177.
9. Herrmann M, Frangou CG, Kirschbaum B. Effects of leflunomide on early T cell signaling and cell cycle commitment. Rheumatol Eur 1997;26(suppl. 2):63.
10. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong ASF. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997;159:22-7.
11. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;25(suppl. 53):20-6.
12. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol 1999;162:2095-102.
13. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997;40:598-609.
14. Breedveld FC. New insights in the pathogenesis of rheumatoid arthritis. J Rheumatol 1998;25(suppl. 53):3-7.
15. Smolen JS, Tohidast-Akrad M, Gal A et al. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol 1996;25:1-4.
16. Feldman M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
17. Steiner G, Tohidast-Akrad M, Witzmann G et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 1999;38:202-13.
18. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989;32:531-7.
20. Smolen JS, Breedveld FC, Eberl G et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38: 38-43.
21. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
22. Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol 1999;26:712-6.
23. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis Rheum 1971;14:706-20.
24. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
25. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159: 2542-50.
26. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Rheumatology 2000;39:in press.
27. Emery P, Breedveld FC, Lemmel EM, Rosenberg R, Loew-Friedrich I. A phase III, randomized, double-blind study of leflunomide versus methotrexate in rheumatoid arthritis. Presented at the XIV EULAR Congress 1999; 103 Abstract no. 399.
28. Paulus HE, Egger MJ, Ward JR, Williams JH and the Cooperative Systemic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
29. Larsen A, Kalden JR, Scott DL et al. Retardation of structural damage with leflunomide in rheumatoid arthritis assessed by Larsen Methodology: 2-year results. Arthritis Rheum 1999;42(suppl. 9):S82.
30. Hannonen P, Möttönen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. Arthritis Rheum 1993;36: 1501-9.
31. Forre Ø, Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum 1994;37:1506-12.
32. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human IL-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
33. Morgan SL, Baggott JE, Vaughn, WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
34. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;1:36-43.
35. Van Ede A, Laan R, Rood M et al. Effect of folic and folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double-blind, 48-week, clinical trial. Arthritis Rheum 1999;42(suppl. 9):S380.
36. Kalden JR, Schattenkircher M, Smolen JS et al. Leflunomide vs sulfasalazine in rheumatoid arthritis: 24-month update of a randomized, double-blind study. Arthritis Rheum 1999;42(suppl. 9):S271.
37. Cohen S, Weaver A, Schiff V for the Leflunomide Study Group. Two-year treatment of active rheumatoid arthritis (RA) with leflunomide (LEF) compared with placebo (PL) or methotrexate (MTX). Arthritis Rheum 1999; 42(suppl. 9):S271.